Pruvanserin

Drug Profile

Pruvanserin

Alternative Names: EMD 281014; LSN2411347; LY-2422347

Latest Information Update: 19 Aug 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck KGaA
  • Developer Eli Lilly; Newron Pharmaceuticals
  • Class Piperazines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported CNS disorders
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 19 Aug 2014 No development reported - Phase-I for CNS disorders in Italy (PO)
  • 21 Aug 2012 Phase-I clinical trials in CNS disorders in Italy (unspecified route)
  • 05 Apr 2011 Discontinued - Phase-II for Insomnia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top